Kiniksa Pharmaceuticals International PLC
KNSA32.400USD
+0.420+1.31%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.40BCap. mercado
PérdidaP/E TTM
Más Datos de Kiniksa Pharmaceuticals International PLC Compañía
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
Información de la empresa
Símbolo de cotizaciónKNSA
Nombre de la empresaKiniksa Pharmaceuticals International PLC
Fecha de salida a bolsaMay 24, 2018
Director ejecutivoMr. Sanjiv K. (Sanj) Patel
Número de empleados315
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 24
Dirección23 Old Bond Street, Floor 3
CiudadLONDON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalWIS 4PZ
Teléfono
Sitio Webhttps://www.kiniksa.com/
Símbolo de cotizaciónKNSA
Fecha de salida a bolsaMay 24, 2018
Director ejecutivoMr. Sanjiv K. (Sanj) Patel
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 22 de may
Actualizado: jue., 22 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
Accionistas
Accionistas
Proporción
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
41.14%
Investment Advisor
27.15%
Investment Advisor/Hedge Fund
25.63%
Individual Investor
3.86%
Research Firm
2.27%
Pension Fund
0.59%
Bank and Trust
0.30%
Insurance Company
0.11%
Family Office
0.10%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
393
42.78M
98.41%
-554.60K
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
2023Q1
303
35.17M
100.37%
-5.41M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Rubric Capital Management LP
3.38M
7.99%
+764.14K
+29.18%
Mar 31, 2025
The Vanguard Group, Inc.
3.35M
7.91%
+151.60K
+4.74%
Mar 31, 2025
Baker Bros. Advisors LP
2.82M
6.66%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
5.94%
-39.60K
-1.55%
Mar 31, 2025
Tang Capital Management, LLC
2.12M
5%
+1.49M
+237.03%
Mar 31, 2025
Braidwell LP
1.96M
4.64%
-1.49M
-43.14%
Mar 31, 2025
Point72 Asset Management, L.P.
1.15M
2.71%
+1.15M
--
Mar 31, 2025
Pictet Asset Management Ltd.
1.13M
2.68%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
1.10M
2.6%
+1.10M
--
Mar 31, 2025
Desnick (Robert)
1.05M
2.48%
--
--
Apr 08, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
1.92%
First Trust Active Factor Small Cap ETF
0.54%
VictoryShares Small Cap Free Cash Flow ETF
0.53%
iShares Health Innovation Active ETF
0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.15%
WisdomTree US SmallCap Fund
0.15%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
Fidelity Enhanced Small Cap ETF
0.11%
iShares Micro-Cap ETF
0.04%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción1.92%
First Trust Active Factor Small Cap ETF
Proporción0.54%
VictoryShares Small Cap Free Cash Flow ETF
Proporción0.53%
iShares Health Innovation Active ETF
Proporción0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.15%
WisdomTree US SmallCap Fund
Proporción0.15%
ProShares Ultra Nasdaq Biotechnology
Proporción0.13%
Invesco Nasdaq Biotechnology ETF
Proporción0.13%
Fidelity Enhanced Small Cap ETF
Proporción0.11%
iShares Micro-Cap ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
